Hdac1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Histone Deacetylase 1 (HDAC1) is a member of the class I histone deacetylases that plays a central role in epigenetic regulation of gene expression[1]. It catalyzes the removal of acetyl groups from lysine residues on histone tails, leading to chromatin condensation and transcriptional repression. HDAC1 is implicated in numerous neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, making it an important therapeutic target[2].
| HDAC1 Protein | |
|---|---|
| Protein Name | Histone Deacetylase 1 |
| Gene | HDAC1 |
| UniProt ID | Q13547 |
| PDB ID(s) | 1C3R, 4BKX, 5IGW |
| Molecular Weight | 55 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Class I HDACs |
| Expression | Ubiquitous, high in brain |
HDAC1 functions as part of multi-protein complexes[3]:
HDAC1 alterations in AD include[4]:
| Drug | Class | Clinical Status | Disease |
|---|---|---|---|
| Vorinostat | Pan-HDAC | Approved (CTCL) | Cancer |
| Valproic acid | Pan-HDAC | Approved (seizures) | Epilepsy |
| Entinostat | Class I | Clinical trials | Various |
| RGFP966 | HDAC3-selective | Preclinical | Various |
The study of Hdac1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Yang XJ, Seto E. (2008). "The Rpd3/Hda1 family of histone deacetylases." Mol Cell. 32(1):39-49. PMID:18951088. ↩︎
Gräff J, Tsai LH. (2013). "Histone acetylation: molecular mnemonics on the chromatin." Nat Rev Neurosci. 14(2):97-111. PMID:23324611. ↩︎
Kadamb R, et al. (2013). "Sin3: insight into its transcription regulatory functions." FEBS J. 280(22):5669-5678. PMID:24164893. ↩︎
Haberl M, et al. (2015). "Acetylation: a novel therapeutic target for Alzheimer's disease?" Neurodegener Dis. 15(2):83-95. PMID:25591767. ↩︎